Like many of us have been saying for months @Joelsmith2452 , the KPI's could be as minor as the Kuwait VivaGel® BV approval mentioned in the Quarterly ... you know the country with a population of around 4 million people ?
We know it certainly couldn't be based on "receipts from customers" given the dismal figures reported in the last 12 months
However you look at it, it's certainly a slap in the face to long term shareholders given the company's poor performance over the last 12 months....... not to mention the disappointing outlook presented in the Quarterly Starpharma just released this week, especially regarding the never ending in house DEP® trials .....
I note the cat still has some people's tongues in relation to the Quarterly report but I can certainly understand why they are quiet on the matter .....
GLTAH
